PGNX Progenics Pharmaceuticals Inc.

4.6
-0.09  -2%
Previous Close 4.69
Open 4.66
Price To Book 3.38
Market Cap 388895564
Shares 84,542,514
Volume 850,807
Short Ratio
Av. Daily Volume 1,415,747

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181223144
  2. 8-K - Current report 181214499
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169597
  4. 8-K - Current report 181168247
  5. EFFECT - Notice of Effectiveness 181137470

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing of first patient announced December 3, 2018. Data due early 2020.
PyL
Prostate cancer
FDA approval announced July 30, 2018.
Azedra
Pheochromocytoma
Phase 3 trial met one of two co-primary endpoints.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).
Phase 1 trial ongoing.
1095
Prostate Cancer

Latest News

  1. Here Are 3 Small-Cap Names for Biotech Investors to Consider
  2. What Did Progenics Pharmaceuticals, Inc.’s (NASDAQ:PGNX) CEO Take Home Last Year?
  3. Should You Buy NanoString Technologies Inc (NSTG)?
  4. Is Noodles & Co (NDLS) A Good Stock To Buy?
  5. Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer
  6. Research Report Identifies Capstone Turbine, LivePerson, Diamondback Energy, Presidio, Pretium Resources, and Progenics Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  7. Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at the Radiological Society of North America (RSNA) Annual Meeting
  8. Edited Transcript of PGNX earnings conference call or presentation 8-Nov-18 1:30pm GMT
  9. Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates
  10. Progenics: 3Q Earnings Snapshot
  11. Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
  12. Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8
  13. Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth
  14. The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
  15. Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA
  16. Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine
  17. Generic-Drugs Stock Outlook: No Respite from Pricing Issues
  18. Progenics On Positive Prostate Cancer Imaging Data: 'These Are Highly Encouraging Results'
  19. Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181223144
  2. 8-K - Current report 181214499
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169597
  4. 8-K - Current report 181168247
  5. EFFECT - Notice of Effectiveness 181137470
  6. CORRESP [Cover] - Correspondence
  7. CORRESP [Cover] - Correspondence
  8. UPLOAD [Cover] - SEC-generated letter
  9. 8-K - Current report 181120652
  10. S-3 - Registration statement under Securities Act of 1933 181120397